HemoBioTech, Inc. (OTC BB: HMBT), a biopharmaceutical company, is focused on developing HemoTech™, which may be the first viable substitute for human blood. HemoTech™, the company’s core product, is a bovine-hemoglobin (Hb) based human blood substitute that has the capability of replacing red blood cells in the human body. The company has an exclusive worldwide license for HemoTech, and intends to use its technology to meet the increasing demand for safe and inexpensive human blood substitute product around the world. For further information, visit the Company’s web site at www.hemobiotech.com.
- 17 years ago
QualityStocks
HemoBioTech, Inc. (OTC BB: HMBT)
Tags Rodman & Renshaw
Related Post
-
Silvercorp Metals Inc. (NYSE-A/TSX: SVM) Added to S&P/TSX Composite Index After a Year of Growth
Disseminated on behalf of Silvercorp Metals Inc. (NYSE-A/TSX: SVM) and includes paid advertisement. Analysts remain…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Expands LIFE Investment Opportunity Amid Ramp-up to Abitibi Belt Production
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may include…
-
QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Establishes Snapt Beverages as Vertically Integrated Manufacturing and Brand Platform
Golden Triangle Ventures (OTC: GTVH) (“GTV”) announced the establishment of Snapt Beverages as its manufacturing and…